Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk management program couldn't save psoriasis drug. Decision is final, firm says.

You may also be interested in...



Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006

Roche Wins Genentech After Months-Long Battle

The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.

Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials

President Obama praises Hamburg's "reputation of integrity" and record of public health acheivements in making nominations March 14.

Related Content

Topics

UsernamePublicRestriction

Register

PS069393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel